Key Takeaways GLP-1, a hormone that regulates blood sugar and appetite, has gained popularity due to its effectiveness in treating type-2 diabetes and aiding weight loss
Some customers use US delivery from Canada when arranging ongoing cardiovascular medicines
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial
Pregnancy or Breastfeeding: Use is not recommended due to a lack of sufficient safety data
the standard BNF loading regimen is 1 mg on alternate days for two weeks, followed by 1 mg every three months for maintenance
Patients should confirm they are administering injections consistently on the same day each week and have reached an appropriate maintenance dose, as suboptimal dosing may limit weight loss potential